Literature DB >> 10972499

Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?

A Bertoletti1, M K Maini.   

Abstract

During infection with hepatitis B or C viruses, cytotoxic T lymphocytes (CTLs) have been implicated as both the mediators of protection and the principal effectors of liver pathology. Recent studies have allowed an investigation of the relationship between virus-specific CTL responses, liver damage and viral replication. In the presence of an efficient virus-specific CTL response, a scenario is emerging where inhibition of viral replication can be independent of liver pathology. We discuss the possibility that an inadequate CTL response--unable to control viral replication--may contribute to liver pathology not only directly but also via the recruitment of non-virus-specific T cells.

Entities:  

Mesh:

Year:  2000        PMID: 10972499     DOI: 10.1016/s1369-5274(00)00109-0

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  21 in total

Review 1.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis.

Authors:  Hai-Xia Wang; Man Liu; Shun-Yan Weng; Jing-Jing Li; Chao Xie; Hong-Lin He; Wen Guan; Yun-Sheng Yuan; Jin Gao
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

2.  Role natural killer group 2D-ligand interactions in hepatitis B infection.

Authors:  Teresa Pollicino; Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-04-28

3.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

4.  Changes in count and function of splenic lymphocytes from patients with portal hypertension.

Authors:  Zong-Fang Li; Shu Zhang; Gao-Bo Lv; Ying Huang; Wei Zhang; Song Ren; Jun Yang; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

5.  Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.

Authors:  Jocelyn L Tan-Shalaby
Journal:  BMJ Case Rep       Date:  2014-09-01

6.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.

Authors:  H J Flink; D Sprengers; B E Hansen; M van Zonneveld; R A de Man; S W Schalm; H L A Janssen
Journal:  Gut       Date:  2005-05-29       Impact factor: 23.059

7.  Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.

Authors:  Xue-Ping Nan; Ye Zhang; Hai-Tao Yu; Rui-Lin Sun; Mei-Juan Peng; Yu Li; Wen-Jing Su; Jian-Qi Lian; Jiu-Ping Wang; Xue-Fan Bai
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

8.  Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.

Authors:  Burkhard J Manfras; Hans Weidenbach; Karl-Heinz Beckh; Peter Kern; Peter Möller; Guido Adler; Thomas Mertens; Bernhard O Boehm
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

9.  Frequencies and characterization of HBV-specific cytotoxic T lymphocytes in self-limited and chronic hepatitis B viral infection in China.

Authors:  Xinxing Yang; Youhua Hao; Zhi Liu; Ling Chen; Honghui Ding; Xiping Zhao; Mengji Lu; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

10.  Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1''-phosphatase, a viral function conserved in the alpha-like supergroup.

Authors:  Klara Kristin Eriksson; Luisa Cervantes-Barragán; Burkhard Ludewig; Volker Thiel
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.